Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kuros Biosciences ( (CH:KURN) ) has shared an update.
Kuros Biosciences is addressing media inquiries regarding the resignation of former Board member Albert Arp, who allegedly shared price-sensitive information with an unrelated third party. The company is conducting an internal investigation but assures that this issue does not affect its strategic direction, financial results, or operations.
The most recent analyst rating on (CH:KURN) stock is a Buy with a CHF32.50 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
More about Kuros Biosciences
Kuros Biosciences is a company focused on discovering, developing, and delivering innovative biologic technologies. With operations in the United States, Switzerland, and the Netherlands, it is listed on the SIX Swiss Exchange. The company’s flagship product, MagnetOs, is an advanced bone graft used globally, known for its unique technology that stimulates bone growth without added cells or growth factors.
Average Trading Volume: 239,328
Technical Sentiment Signal: Buy
Current Market Cap: CHF867.1M
Learn more about KURN stock on TipRanks’ Stock Analysis page.